374. A Multicenter Open-Label Single-Arm Clinical Trial of Combination Therapy of Surgery, Itraconazole, Doxycycline, and Azithromycin for Vascular Pythiosis
Rattachement africain : us, th. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Background Vascular pythiosis, caused by Pythium insidiosum, is a neglected, life-threatening condition which carried a 100% mortality rate, within 3 months, among patients with residual disease after surgery, regardless of antifungal treatment. Recently, Thai P. insidiosum isolates were found to susceptible to doxycycline and azithromycin, with evidence of synergy. We report results of a clinical trial from 15 centers in Thailand (Thai Clinical Trial Registry number TCTR20191217006). Methods This study enrolled patients with vascular pythiosis who had 2 of the 4 diagnostic criteria: consistent clinical presentation, positive serum P. insidiosum-specific antibodies, positive cultures, or positive histopathology. All received surgery, itraconazole, doxycycline, and azithromycin. Patients were followed up until 6 months after diagnosis. Subsequent follow-ups after 6 months were at the clinician’s discretion if there were any concerns for residual diseases or unresectable arterial lesions. Results 40 patients were enrolled, with a median age (interquartile range [IQR]) of 51 (45-56) years. 38 (95%) had major thalassemia, 1 (2.5%) had liver cirrhosis, and 1 (2.5%) had myeloproliferative syndrome. None had known immunocompromised conditions. After surgery, 14 (35%) still had residual diseases. At 6 months after diagnosis, 3 (7.5%) patients died (disseminated pythiosis, sepsis with multi-organ failure, and ESBL Klebsiella pneumoniae bacteremia). Among patients with residual disease, 1 (7.1%) died and 13 are still alive. Median follow-up time (IQR) among patients with residual disease was 385 (209-622) days. There were no statistical differences in time from onset to surgery and time from onset to first antimicrobial between patients with and without residual disease after surgery (Table). One patient had to stop doxycycline prematurely due to photosensitivity. Patient characteristics IQR: interquartile range; N: number Conclusion The new treatment combination with surgery, itraconazole, azithromycin, and doxycycline improved survival among patients with vascular pythiosis who had residual disease. Disclosures Nitipong Permpalung, MD, MPH, Alcimed: Advisor/Consultant|CareDx: Grant/Research Support|Cidara Therapeutics: Grant/Research Support|Clarion: Advisor/Consultant|ClearView: Advisor/Consultant|IMMY Diagnostics: Grant/Research Support|Merck: Grant/Research Support|Scynexis: Grant/Research Support
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- 374. A Multicenter Open-Label Single-Arm Clinical Trial of Combination Therapy of Surgery, Itraconazole, Doxycycline, and Azithromycin for Vascular Pythiosis
- Date Crossref
- 27/11/2023
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Johns Hopkins University Infectious Disease pays non établi dans la noticeUniversité ou école supérieure
-
Johns Hopkins Medicine pays non établi dans la noticeÉtablissement de santé
-
Chulalongkorn University pays non établi dans la noticeUniversité ou école supérieure
-
King Chulalongkorn Memorial Hospital pays non établi dans la noticeÉtablissement de santé
-
Khon Kaen University pays non établi dans la noticeUniversité ou école supérieure
-
University of Miami pays non établi dans la noticeUniversité ou école supérieure
-
Jackson Memorial Hospital pays non établi dans la noticeÉtablissement de santé
-
Sappasithiprasong Hospital pays non établi dans la noticeÉtablissement de santé
-
Maharat Nakhon Ratchasima Hospital pays non établi dans la noticeÉtablissement de santé
-
Nan Hospital pays non établi dans la noticeÉtablissement de santé
-
Buddhachinaraj Hospital pays non établi dans la noticeÉtablissement de santé
-
ChiangRai Prachanukroh Hospital pays non établi dans la noticeÉtablissement de santé
Infectious Disease — Johns Hopkins University, Johns Hopkins Medicine et Chulalongkorn University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.